198 related articles for article (PubMed ID: 17237277)
1. HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor.
Kogan NM; Schlesinger M; Priel E; Rabinowitz R; Berenshtein E; Chevion M; Mechoulam R
Mol Cancer Ther; 2007 Jan; 6(1):173-83. PubMed ID: 17237277
[TBL] [Abstract][Full Text] [Related]
2. HU-331 is a catalytic inhibitor of topoisomerase IIα.
Regal KM; Mercer SL; Deweese JE
Chem Res Toxicol; 2014 Dec; 27(12):2044-51. PubMed ID: 25409338
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid Quinones-A Review and Novel Observations.
Kogan NM; Peters M; Mechoulam R
Molecules; 2021 Mar; 26(6):. PubMed ID: 33801057
[TBL] [Abstract][Full Text] [Related]
4. HU-331 and Oxidized Cannabidiol Act as Inhibitors of Human Topoisomerase IIα and β.
Wilson JT; Fief CA; Jackson KD; Mercer SL; Deweese JE
Chem Res Toxicol; 2018 Feb; 31(2):137-144. PubMed ID: 29272108
[TBL] [Abstract][Full Text] [Related]
5. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
Kassab AE; Gedawy EM
Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
[TBL] [Abstract][Full Text] [Related]
6. A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study.
Kogan NM; Schlesinger M; Peters M; Marincheva G; Beeri R; Mechoulam R
J Pharmacol Exp Ther; 2007 Aug; 322(2):646-53. PubMed ID: 17478614
[TBL] [Abstract][Full Text] [Related]
7. Monocyclic Quinone Structure-Activity Patterns: Synthesis of Catalytic Inhibitors of Topoisomerase II with Potent Antiproliferative Activity.
Waugh TM; Masters J; Aliev AE; Marson CM
ChemMedChem; 2020 Jan; 15(1):114-124. PubMed ID: 31778038
[TBL] [Abstract][Full Text] [Related]
8. HU-331: a cannabinoid quinone, with uncommon cytotoxic properties and low toxicity.
Peters M; Kogan NM
Expert Opin Investig Drugs; 2007 Sep; 16(9):1405-13. PubMed ID: 17714026
[TBL] [Abstract][Full Text] [Related]
9. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.
Pourpak A; Landowski TH; Dorr RT
J Pharmacol Exp Ther; 2007 Jun; 321(3):1109-17. PubMed ID: 17351106
[TBL] [Abstract][Full Text] [Related]
10. A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells.
Kogan NM; Blázquez C; Alvarez L; Gallily R; Schlesinger M; Guzmán M; Mechoulam R
Mol Pharmacol; 2006 Jul; 70(1):51-9. PubMed ID: 16571653
[TBL] [Abstract][Full Text] [Related]
11. A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells.
Patra N; De U; Kang JA; Kim JM; Ahn MY; Lee J; Jung JH; Chung HY; Moon HR; Kim HS
Eur J Pharmacol; 2011 May; 658(2-3):98-107. PubMed ID: 21376033
[TBL] [Abstract][Full Text] [Related]
12. Cyclohexa-2,5-diene-1,4-dione-based antiproliferative agents: design, synthesis, and cytotoxic evaluation.
Petronzi C; Festa M; Peduto A; Castellano M; Marinello J; Massa A; Capasso A; Capranico G; La Gatta A; De Rosa M; Caraglia M; Filosa R
J Exp Clin Cancer Res; 2013 Apr; 32(1):24. PubMed ID: 23631805
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerases as anticancer targets.
Delgado JL; Hsieh CM; Chan NL; Hiasa H
Biochem J; 2018 Jan; 475(2):373-398. PubMed ID: 29363591
[TBL] [Abstract][Full Text] [Related]
14. Tackling the Cytotoxic Effect of a Marine Polycyclic Quinone-Type Metabolite: Halenaquinone Induces Molt 4 Cells Apoptosis via Oxidative Stress Combined with the Inhibition of HDAC and Topoisomerase Activities.
Shih SP; Lee MG; El-Shazly M; Juan YS; Wen ZH; Du YC; Su JH; Sung PJ; Chen YC; Yang JC; Wu YC; Lu MC
Mar Drugs; 2015 May; 13(5):3132-53. PubMed ID: 26006712
[TBL] [Abstract][Full Text] [Related]
15. Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors.
Eissa IH; Metwaly AM; Belal A; Mehany ABM; Ayyad RR; El-Adl K; Mahdy HA; Taghour MS; El-Gamal KMA; El-Sawah ME; Elmetwally SA; Elhendawy MA; Radwan MM; ElSohly MA
Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900123. PubMed ID: 31463953
[TBL] [Abstract][Full Text] [Related]
16. Producing irreversible topoisomerase II-mediated DNA breaks by site-specific Pt(II)-methionine coordination chemistry.
Wang YR; Chen SF; Wu CC; Liao YW; Lin TS; Liu KT; Chen YS; Li TK; Chien TC; Chan NL
Nucleic Acids Res; 2017 Oct; 45(18):10861-10871. PubMed ID: 28977631
[TBL] [Abstract][Full Text] [Related]
17. N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase.
Baviskar AT; Madaan C; Preet R; Mohapatra P; Jain V; Agarwal A; Guchhait SK; Kundu CN; Banerjee UC; Bharatam PV
J Med Chem; 2011 Jul; 54(14):5013-30. PubMed ID: 21644529
[TBL] [Abstract][Full Text] [Related]
18. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
[TBL] [Abstract][Full Text] [Related]
20. 4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer.
Reddy VG; Bonam SR; Reddy TS; Akunuri R; Naidu VGM; Nayak VL; Bhargava SK; Kumar HMS; Srihari P; Kamal A
Eur J Med Chem; 2018 Jan; 144():595-611. PubMed ID: 29289884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
